bisantrene has been researched along with Carcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Copeland, LJ; Gershenson, DM; Kavanagh, JJ; Saul, PB | 1 |
| Feun, LG; Loo, TL; Lu, K; Savaraj, N; Umsawasdi, T; Yap, BS | 1 |
| Alberts, DS; Boutselis, JG; Cowan, JD; Neilan, BA; Surwit, EA | 1 |
3 other study(ies) available for bisantrene and Carcinoma
| Article | Year |
|---|---|
A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.
Topics: Adult; Aged; Anthracenes; Carcinoma; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms | 1986 |
Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Topics: Adult; Aged; Anthracenes; Carcinoma; Chromatography, High Pressure Liquid; Drug Evaluation; Female; Half-Life; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Regression Analysis | 1986 |
Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Anthracenes; Antibiotics, Antineoplastic; Carcinoma; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms | 1986 |